Lipoprotein(a) as well as two oxidized phospholipids (OxPLs) are all associated with multivessel coronary artery disease detected on angiography and also linked to a higher risk of major adverse ...

Michael D. Shapiro, DO, discusses how lipoproteins, chiefly LDL (low-density lipoprotein) and Lp(a) (lipoprotein a), drive atherosclerotic heart disease. This is a video synopsis/summary of an ...

Icosapent ethyl (Vascepa; Amarin) remains effective at reducing cardiovascular events in patients with elevated triglycerides but relatively well-controlled LDL cholesterol on a statin irrespective of ...

Please provide your email address to receive an email when new articles are posted on . Lipoprotein(a) should be measured in all people at least once. “Evaluation and management of Lp(a) is actionable ...

Please provide your email address to receive an email when new articles are posted on . Lepodisiran greatly lowered lipoprotein(a) at 6 months and 1 year compared with placebo. A cardiovascular ...

The evidence implicating high levels of lipoprotein(a), or Lp(a), as a risk predictor for heart attack, stroke, and other cardiovascular conditions has outpaced the science of what to do about the ...

Experts discuss the current prevalence of lipoprotein(a) (Lp[a]) testing in the US, both in the general population and among those with established atherosclerotic cardiovascular disease (ASCVD), its ...

Whether to measure Lp(a), a lipoprotein associated with increased cardiovascular risk, and how to use that information in risk assessment is a hot topic in cardiovascular medicine. The American Heart ...